Class / Patent application number | Description | Number of patent applications / Date published |
546080000 | Plural ring hetero atoms in the tricyclo ring system | 89 |
20090069564 | Methods and Compositions for Selectin Inhibition - The present invention relates to the field of anti-inflammatory substances, and more particularly to novel compounds that act as antagonists of the mammalian adhesion proteins known as selectins. In some embodiments, methods for treating selectin mediated disorders are provided which include administration of compound of Formula I: | 03-12-2009 |
546081000 | Plural ring nitrogens in the tricyclo ring system | 59 |
20080214818 | Organic metal complexes - An organic metal complex is provided. The organic metal complex has formula (I): | 09-04-2008 |
20110178303 | PIGMENT COMPOUND, METHOD OF PRODUCING THE SAME, AND COLORING AGENT - An object of the present invention is to provide a novel plant-derived pigment compound, which is a pigment compound represented by Formula II: | 07-21-2011 |
20110237797 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS - Disclosed herein are compounds represented by the structural formula: | 09-29-2011 |
20160122348 | COMPOUNDS AND ANTI-TUMOR NQO1 SUBSTRATES - Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy. | 05-05-2016 |
20160185781 | 1,9-DIAZAPHENALENE DERIVATIVE AND PROCESS FOR MANUFACTURING THE SAME - A 1,9-diazaphenalene derivative is represented by | 06-30-2016 |
546082000 | Three or more ring hetero atoms in the tricyclo ring system | 20 |
20080249310 | Process For the Preparation of (2R,3R)-2-Hydroxy-3-Amino-3-Aryl-Propionamide and (2R,3R)-2-Hydroxy-3-Amino-3-Aryl-Propionic Acid Alkyl Ester - The invention relates to a novel compound (2R,3R)-2-hydroxy-3-amino-3-aryl-propionamide according to formula (1), wherein aryl A represents a substituted or unsubstituted aromatic ring, | 10-09-2008 |
20080306266 | Process for Preparing 2-Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine - The invention provides various processes for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine. | 12-11-2008 |
20090005566 | Method for Making 1-Substituted 1H-Imidazo [4,5-C] Quinolin-4-Amine Compounds and Intermediates Therefor - The present invention concerns a method for manufacturing 1-substituted 1H imidazo[4,5-c]quinolin-4-amine compounds through their corresponding formamides. The invention also concerns new formamide intermediates. | 01-01-2009 |
20090209764 | Process for Preparation of 4-amino-1-isobutyl-1H-Imidazo[4,5-C]-quinoline (Imiquimod) - A process for the preparation of imiquimod comprising oxidation of 1-Isobutyl- | 08-20-2009 |
20090240055 | Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof - Methods and intermediates for preparing compounds of the Formulas: (I and X) are disclosed. The methods include a method providing a compound of the Formula: (IV) and converting a compound of Formula IV to a compound of Formula I, a method providing a compound of the Formula: (VIII) and converting a compound of Formula VIII to a compound of Formula I, and a method providing a compound of the Formula: (XI) and converting a compound of Formula XI to a compound of Formula I. | 09-24-2009 |
20100184984 | METHOD OF PREPARING 4-AMINO-1H-IMIDAZO (4,5-C) QUINOLINES AND ACID ADDITION SALTS THEREOF - The present invention provides a method of preparing a 4-(arylmethyl)amino-1H-imidazo(4,5-c)quinoline of formula (4) by reacting an arylmethylamine of formula (3) with a 4-chloro-1H-imidazo(4,5-c)quinoline of formula (2). The present invention further provides a method of preparing an acid addition salt of formula (5) comprising the step of hydrolyzing a 4-(arylmethyl)amino-1H-imidazo(4,5-c)quinoline of formula (4) with a strong acid, HX. The present invention further provides a method of preparing a 4-amino-1H-imidazo(4,5-c)quinoline of formula (1) comprising the step of treating an acid addition salt of formula (5) with a base. | 07-22-2010 |
20100292477 | SOLID FORMS AND PROCESS FOR PREPARING - The present invention provides amorphous solid forms of the compound of Formula I, as well as methods for preparing the compound of Formula I by precipitation. | 11-18-2010 |
20110034691 | Process for the Production of Fused, Tricyclic Sulfonamides - The present invention provides methods, i.e., scalable or large-scale processes for the production of fused, tricyclic sulfonamido analogs, such as substituted or unsubstituted 5-(aryl-sulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinolines and 5-(heteroaryl-sulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinolines. Exemplary methods of the invention include an intra-molecular cyclization step, in which a carbon-nitrogen bond is formed, and which employs a copper-based catalyst that contains at least one organic ligand, such as DMEDA. The invention further provides compounds, which are useful as intermediates in the methods of the invention. | 02-10-2011 |
20110046377 | TETRAHYDROPYRIDOETHERS FOR TREATMENT OF AMD - A medication comprising tetrahydropyridoethers for use in the treatment of AMD. | 02-24-2011 |
20110184176 | PRODUCING METHOD OF NITROGEN CONTAINING CONDENSED HETEROCYCLIC COMPOUND - Provided is a method for producing a nitrogen-containing condensed heterocyclic compound containing the step of: reacting a compound represented by Formula (1a) or Formula (1b) with a compound represented by Formula (2) under existence of cupper or a cupper ion, and a ligand to produce a nitrogen-containing condensed heterocyclic compound represented by Formula (3a) or Formula (3b): | 07-28-2011 |
20110269965 | Ring Closing and Related Methods and Intermediates - Methods and intermediates useful for making compounds of the formula: and the preparation of compounds of Formula I, preferably including the formation of intermediate compounds of the formula: | 11-03-2011 |
20120165531 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof - The invention relates to tricyclic N-heteroaryl-carboxamide derivatives having the formula (I): | 06-28-2012 |
20120302755 | Imaging Agents for Detecting Neurological Dysfunction - Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled carbazoles and derivatives thereof and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease. | 11-29-2012 |
20130245266 | SOLID FORMS AND PROCESS FOR PREPARING - The present invention provides amorphous solid forms of the compound of Formula I, as well as methods for preparing the compound of Formula I by precipitation. | 09-19-2013 |
20140194628 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS - Imidazo ring systems substituted at the 1-position, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 07-10-2014 |
20140336385 | TRIAZOLIUM AND TETRAZOLIUM DERIVATIVES AS ORGANIC LIGHT EMITTERS - Provided herein are organic compounds useful in a variety of OLED applications. | 11-13-2014 |
20160046623 | SALT OF PYRAZOLOQUINOLINE DERIVATIVE, AND CRYSTAL THEREOF - The present invention provides a salt of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, malonic acid, maleic acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid; or a crystal thereof with a potential to be used as drug substance in pharmaceuticals. | 02-18-2016 |
20160194322 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 07-07-2016 |
546083000 | At least one of the ring hetero atoms is chalcogen | 2 |
20140094608 | MODIFIED CARBOCYANINE DYES AND THEIR CONJUGATES - Chemically reactive carbocyanine dyes incorporating an indolium ring moiety that is substituted at the 3-position by a reactive group or by a conjugated substance, and their uses, are described. Conjugation through this position results in spectral properties that are uniformly superior to those of conjugates of spectrally similar dyes wherein attachment is at a different position. The invention includes derivative compounds having one or more benzo nitrogens. | 04-03-2014 |
20150344497 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO - This invention relates to processes for preparing a JAK1 inhibitor having Formula Ia: | 12-03-2015 |
546084000 | One of the cyclos is five-membered | 28 |
20090192312 | Brain Function-Improving Agent, and Functional Food Containing the Improving Agent - There are provided a brain function improving agent having an effect of improving learning and memory abilities, and a functional food containing the function improving agent. A preparation comprising a pyrroloquinoline quinone or a salt thereof alone or in combination with coenzyme Q10 and a functional food containing the preparation can improve learning and memory abilities decreased due to brain function disorders caused by various factors. | 07-30-2009 |
20090270625 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF - The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) | 10-29-2009 |
20090326229 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF - To provide methods for preparing alpha-carboline derivatives in few steps, as well as conveniently and industrially advantageously. A method for preparation of a compound represented by Formula (II) or a salt thereof, comprising subjecting a compound represented by Formula (I) or a salt thereof to a ring closure reaction in the presence of a palladium catalyst, a ligand, and a base; a method for preparation of a compound represented by Formula (IX) or a salt thereof, comprising subjecting a compound represented by Formula (VII) or a salt thereof to a ring closure reaction in the presence of a palladium catalyst, a ligand, and a base, and subsequently to an aromatization reaction; and methods for preparation of compounds represented by Formulae (XV), (XVII), and (XIX) or a salt thereof, comprising subjecting respective compounds represented by Formulae (II) and (IX) or a salt thereof to a reaction for introducing a leaving group when necessary, and subsequently to a coupling reaction: wherein the symbols respectively represent the same meaning as defined in the present specification. | 12-31-2009 |
20110245503 | ENANTIOSELECTIVE SYNTHESIS OF ASYMMETRIC BETA-CARBOLINE INTERMEDIATES - Described herein is a new asymmetric synthesis of imines to obtain β-carboline derivatives useful as key intermediate compounds for the synthesis of phosphodiesterase inhibitors using a new process with palladium or ruthenium hydride and/or nickel boride to reduce chiral intermediates. The use of chloroformate chiral auxiliaries is further described for the reduction and asymmetric hydrogenation of imines to obtain β-carboline derivatives and intermediate compounds used in the preparation thereof. | 10-06-2011 |
20110313164 | LITHIUM DERIVATIVES OF PYRROLOQUINOLINE QUINONE AND PREPARATION METHOD THEREOF - Lithium derivatives of pyrroloquinoline quinone and preparation method thereof are disclosed. In said method, lithium derivatives of pyrroloquinoline quinone are obtained by an acid-base neutralization reaction in a basic solvent with pyrroloquinoline quinine (PQQ) as a starting material. Lithium ion is brought in the molecular structure of pyrroloquinoline quinone to form said lithium derivatives of pyrroloquinoline quinone. The reaction condition of said method is mild, the product is easy to be purified, the preparation procedure is simple, and the yield is more than 80%. Said lithium derivatives of pyrroloquinoline quinone possess GSK-3 inhibiting activity and possess the functions such as reducing the formation of age pigment in the brain of a transgenic mouse and reducing the phosphorylation of tau proteins. Said lithium derivatives of pyrroloquinoline quinone may be used in the manufacture of medicaments for preventing and treating senile dementia, senility or Parkinson's disease. | 12-22-2011 |
20120116087 | CRYSTALS OF PYRROLOQUINOLINEQUINONE SODIUM SALTS - A crystal of pyrroloquinoline quinone disodium salt having peaks at 2θ of 9.1°, 10.3°, 13.8°, 17.7°, 18.3°, 24.0°, 27.4°, 31.2° and 39.5° (±0.2° for each) in powder X-ray diffractometry using Cu Kα radiation, or a crystal of pyrroloquinoline quinone trisodium salt having peaks at 2θ of 6.6°, 11.4°, 13.0°, 22.6°, 26.9°, 27.9°, 37.0°, 38.9° and 43.4° (±0.2° for each) in powder X-ray diffractometry using Cu Kα radiation. | 05-10-2012 |
20120172598 | COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY - The present invention provides compounds having superior TAFIa inhibitory activity. They are dihydroimidazoquinoline compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof: | 07-05-2012 |
20120226045 | PYRROLOQUINOLINE QUINONE IN FREE FORM - An object of the present invention is to provide a method for conveniently producing pyrroloquinoline quinone in the free form without any organic solvent or ion-exchange resin and highly-pure crystals thereof. According to the present invention, there is provided a production method of pyrroloquinoline quinone in the free form and highly-pure crystals thereof, wherein the production method comprises preparing a solution having a pH of 1.5 or less by dissolving an alkali metal salt of pyrroloquinoline quinone to obtain a precipitate. | 09-06-2012 |
20120323009 | PRODUCTION METHOD OF REDUCED PYRROLOQUINOLINE QUINONE - An object of the present invention is to provide a method for conveniently producing reduced pyrroloquinoline quinone from oxidized pyrroloquinoline quinone without needing expensive equipment, and a method for stabilizing reduced pyrroloquinoline quinone. According to the present invention, high-quality reduced pyrroloquinoline quinone can be obtained conveniently and efficiently in a manner suitable for industrial-scale production by mixing pyrroloquinoline quinone and ascorbic acid in a solvent. | 12-20-2012 |
20140128609 | PYRROLOQUINOLINE QUINONE DISODIUM SALT CRYSTAL AND METHOD FOR PRODUCING THE SAME - An object of the present invention is to provide a novel pyrroloquinoline quinone disodium crystal having excellent dispersibility in solvents and excellent permeability through skin, and a method for producing the pyrroloquinoline quinone disodium crystal with high efficiency. According to the present invention, provided are a novel pyrroloquinoline quinone disodium crystal which is produced by drying a crystal produced under specified conditions through a drying means such as lyophilization, ambient drying and vacuum drying, and a method for producing the pyrroloquinoline quinone disodium crystal. | 05-08-2014 |
20140364613 | COMPOUNDS OF 3-(5-SUSTITUTED OXY-2, 4-DINITROPHENYL)-2-OXO-PROPIONIC ACID ESTER, SYNTHESIS AND APPLICATIONS THEREOF - Synthesis of the novel compound 3 (3-(5-substituted Oxy-2,4-dinitro-phenyl)-2-oxo-propionic acid ester) to make Pyrroloquinoline quinone (PQQ) and using it for pharmaceutical purposes is described. More specifically, this disclosure relates to synthesizing the PQQ in an efficient method by using a novel intermediate Formula 1 resulting in a shorter process and higher yield of PQQ. A unique process to make sodium compound of PQQ using either sodium hydroxide and/or sodium carbonate is also shown. | 12-11-2014 |
20150315145 | PROCESS FOR PRODUCING OPTICALLY ACTIVE BICYCLIC UREA COMPOUND - A problem to be solved by the present invention is to provide a process for producing an optically active bicyclic urea compound useful as an intermediate for β-lactamase inhibitor, in a simple and easy manner with high efficiency. | 11-05-2015 |
546085000 | The six-membered hetero ring shares ring members with the five-membered cyclo only (e.g., pyrido-indoles, etc.) | 16 |
20090259043 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS - Compounds of formula (I): | 10-15-2009 |
20100324294 | PROCESS FOR THE PREPARATION OF 2,3,4,9-TETRAHYDRO-1H-BETA-CARBOLIN-3-CARBOXYLIC ACID ESTERS - The present invention relates to the process of preparation of 2,3,4,9-tetrahydro-1/−/-β-carbolin-3-carboxylic acid esters substituted in position 1 of the general formula (I). in the preferred diastereoisomeric form through a single step starting from tryptophan in racemic form and/or its enantiomers and from 3,4-(methylenedioxy)benzaldehyde. | 12-23-2010 |
20120123124 | Manufacturing process for Tadalafil from racemic or L-tryptophan - The present invention relates to a novel manufacturing process of pharmaceutically active compound of formula I, having (6R,12aR)-configuration, used for treatment of erectile dysfunction. Starting from racemic or L-tryptophan the invention describes preparation of an enantiomerically pure intermediate of formula II which is a known precursor in the synthesis of Tadalafil (formula I). | 05-17-2012 |
20120136154 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES - Provided herein are improved processes for the synthesis of substituted tetrahydro beta-carboline derivatives. In particular, provided herein are improved processes useful for the preparation of (S)-4-chlorophenyl 6-chloro-1-(4-methoxyphenyl)-3,4-dihydro-1H-pyrido[3,4- | 05-31-2012 |
20160115162 | Radiosynthesis of Tau Radiopharmaceuticals - This disclosure relates to a one-step method for preparing the tau radiopharmaceutical, [18F]T807, using an unprotected or protected precursor (e.g., tertbutyl 7-(6-nitropyridin-3-yl)-SH-pyrido[4,3-b]indole-5-carboxylate). An improved one-step synthesis method to prepare [18F]T807 was achieved with a protected (e.g., t-BOC) precursor, offering increased solubility, a faster synthesis as well as simpler purification and automation. [18F]T807 was validated for human use with a GE TRACERlab™ FXFN radiosynthesis module. The methodology demonstrated herein should facilitate multi-center trials and widespread use for tauopathy imaging with this radiopharmaceutical. | 04-28-2016 |
546086000 | Chalcogen bonded directly to ring carbon of the tricyclo ring system | 6 |
20090062545 | Trisazo Compound, Ink Composition, Recording Method, and Colored Article - The present invention relates to a trisazo compound represented by the following formula (1) or a salt thereof, | 03-05-2009 |
20100105912 | FLUORO-CONTAINING DERIVATIVES OF HYDROGENATED PYRIDO[4,3-b]INDOLES WITH NEUROPROTECTIVE AND COGNITION ENHANCING PROPERTIES, PROCESS FOR PREPARING, AND USE - Some exemplary embodiments comprise fluoro-containing derivatives of pyrido[4,3-b]indoles (and exemplary methods of making the same) that may be administered to a mammal (including a human) in an effective amount for potential use in the treatment or prophylaxis of neurological disorders including AD, mild cognitive impairment, senile and vascular dementia, HD, ALS, Parkinson's disease, AIDS-related dementia, ischaemic cerebral pathologies, neuropathic pain, ADHD (attention deficit disorder/hyperactivity syndrome), eating disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia (in particular the cognitive deficit of schizophrenia), stroke and also disorders associated with spinal trauma and/or head injury. These derivatives may also be useful for the treatment of borderline personality disorder, obesity, and for use as geroprotectors. The compounds may also be used as “pharmacological tools” for an investigation of the mechanism of protection against neurodegeneration disorders in vivo or in vitro. | 04-29-2010 |
20100145052 | FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY - A fused tricyclic compound having aldose reductase inhibitory activity and shown by the following formula, | 06-10-2010 |
20110046378 | Novel Imaging Agents for Detecting Neurological Dysfunction - Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease | 02-24-2011 |
20120095233 | KINASE INHIBITORS - Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: | 04-19-2012 |
20120178937 | PROCESS FOR THE PREPARATION OF ALOSETRON - The present invention provides an improved process for the preparation of Alosetron of formula (I) and its pharmaceutically acceptable salts. | 07-12-2012 |
546087000 | Nitrogen attached directly or indirectly to the tricyclo ring system by nonionic bonding | 5 |
20090088573 | BIOLOGICALLY ACTIVE PEPTIDES AND COMPOSITIONS, THEIR USE - This invention relates to derivatives of hemiasterlin or Geodiamolide G having anti-mitotic activities and useful in treating cancer. These derivatives are represented by general formula I, | 04-02-2009 |
20100056790 | FLUORO-CONTAINING DERIVATIVES OF HYDROGENATED PYRIDO[4,3-B]INDOLES WITH NEUROPROTECTIVE AND COGNITION ENHANCING PROPERTIES, PROCESS FOR PREPARING, AND USE - Some exemplary embodiments comprise fluoro-containing derivatives of pyrido[4,3-b]indoles (and exemplary methods of making the same) that may be administered to a mammal (including a human) in an effective amount for potential use in the treatment or prophylaxis of neurological disorders including AD, mild cognitive impairment, senile and vascular dementia, HD, ALS, Parkinson's disease, AIDS-related dementia, ischaemic cerebral pathologies, neuropathic pain, ADHD (attention deficit disorder/hyperactivity syndrome), eating disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia (in particular the cognitive deficit of schizophrenia), stroke and also disorders associated with spinal trauma and/or head injury. These derivatives may also be useful for the treatment of borderline personality disorder, obesity, and for use as geroprotectors. The compounds may also be used as “pharmacological tools” for an investigation of the mechanism of protection against neurodegeneration disorders in vivo or in vitro. | 03-04-2010 |
20110245504 | SYNTHESIS OF 9-(ARYLALKYL)-1,2,3,4-TETRAHYDRO-y-CARBOLINE AND ANALOGUES AND INTERMEDIATES - The present invention pertains generally to methods of preparing certain 9-(arylalkyl)-1,2,3,4-tetrahydro-γ-carboline compounds and their analogues, and especially to methods of preparing dimebon. The present invention also pertains to methods of preparing certain intermediate compounds which find use in the synthesis of the 9-(arylalkyl)-1,2,3,4-tetrahydro-γ-carboline compounds. | 10-06-2011 |
20110282063 | METHOD OF PRODUCING A DIAZAFLUORENE COMPOUND - The present invention provides a novel diazafluorene compound for manufacturing a 4,5-diazafluorene derivative. The diazafluorene compound is represented by the general formula (1): | 11-17-2011 |
20130046097 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS - The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines. | 02-21-2013 |
546088000 | Phenanthrolines (including hydrogenated) | 6 |
20090131673 | Electroluminescent Device - Disclosed are electroluminescent devices that comprise organic layers that contain dibenzofuran compounds. The compounds are suitable components of, for example, blue-emitting, durable, organo-electroluminescent layers. The electroluminescent devices may be employed for full color display panels in, for example, mobile phones, televisions and personal computer screens. | 05-21-2009 |
20110009635 | NOVEL NITROGEN-CONTAINING ORGANIC COMPOUNDS USABLE AS CATALYTIC COMPOSITION PRECURSORS - The present invention describes novel nitrogen-containing organic compounds obtained by reacting a compound X of substituted pyridine type comprising at least one ketone function with a compound Y belonging to the aminoquinoleine family and derivatives thereof. Said organic compounds can be used as precursors in a catalytic composition. | 01-13-2011 |
20110251394 | NOVEL ORGANIC COMPOUND - An organic compound is represented by general formula (1): | 10-13-2011 |
20120065402 | ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE - There is provided an organic electronic device having an anode, a hole injection layer, a photoactive layer, an electron transport layer, and a cathode. At least one of the photoactive layer and the electron transport layer includes a compound having Formula I | 03-15-2012 |
20120165532 | One-Step Synthesis Method of 2,9-Dimethyl-4,7-Diphenyl-1,10- Phenanthroline - This invention, which belongs to the field of organic synthesis, involves “One-step synthetic method of 2,9-dimethyl-1,7-diphenyl-1,10-phenanthroline”. This method uses O-phenylenediamine and formula III to react under the condition of mixed-shrinking agent, the synthesis can be completed in one step, the stated mixed-shrinking agent is mixture of hydrochloric acid and organic acid. The organic acid serves as phase transfer catalyst and shrinking agent, meanwhile, as buffer reagent, organic acid reduces polymerization of III, and side products as well. The products gained are of high purity and the reaction is mild and easy to control. Since there is no polluting material added and generated, the waste is safe to discharge. In the after treatment of reaction, ketone solvent is used to reduce separation step and product lost, thus improving yield. | 06-28-2012 |
20140221655 | MODIFIED POLYAROMATIC HYDROCARBONS AND POLYHETEROCYCLICS FOR OPTOELECTRONICS - The invention provides methods for substituting polyaromatic hydrocarbons or polyheterocyclic compounds with perfluoroalkyl groups. The methods can include heating a polyaromatic hydrocarbon substrate or a polyheterocyclic compound substrate in the presence of a perfluoroalkyl iodide, typically in a closed system, wherein the heating is sufficient to bring both the polyaromatic hydrocarbons or polyheterocyclic compound, and the perfluoroalkyl iodide, into the gas phase, thereby allowing the substrate to react with the perfluoroalkyl iodide in the gas phase to form polyaromatic hydrocarbons or polyheterocyclic compounds having one or more perfluoroalkyl substituents. The methods allow for the creation of versatile libraries of novel perfluoroalkyl-containing derivatives that can serve as important building blocks and active components in biomedical, electronic, and materials applications. | 08-07-2014 |
546089000 | Ring oxygen in the tricyclo ring system | 29 |
20080214819 | Process of Producing Bleach Boosters - This invention relates to a process of producing compounds, which are useful as bleach boosters, as well as to the compounds, which are obtainable using said process, and to their use. | 09-04-2008 |
20100137599 | PROCESS FOR PREPARING 1,4-BUTANDIOL MONITRATE - The present invention relates to a process for the preparation of 1,4-butanediol mononitrate as intermediate for large scale preparation of high purity nitrooxybutyl ester of pharmaceutically active compounds. | 06-03-2010 |
20100280247 | PROCESS IMPROVEMENT USING TMEDA - An improved chemical synthesis for compounds having useful biological activity is disclosed, where the use of TMEDA or N,N,N′,N′-tetramethyl-ethane-1,2-diamine gives improved yield. | 11-04-2010 |
20100311976 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES - The invention relates to a novel process for preparing enantiomerically enriched or pure tetrahydroquinoline derivatives by reacting a chiral dihydropyran-methylamine C with a aldehyde B and an aniline A in a multicomponent one pot synthesis in the presence of a protonic acid or Lewis acid with a suitable solvent. A, B, C have the meaning as described in the specification. | 12-09-2010 |
20110021777 | PROCESS IMPROVEMENT - An improved chemical synthesis for intermediates of compounds having useful biological activity is disclosed, where the use of PBr | 01-27-2011 |
20120059169 | NOVEL CRYSTAL FORM OF TRICYCLIC BENZOPYRAN COMPOUND AND PRODUCTION METHOD THEREOF - Crystal forms of (3R,4S)-7-hydroxymethyl-2,2,9-trimethyl-4-(phenethylamino)-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol that are excellent as a drug, and production methods thereof. Production methods include crystallizing (3R,4S)-7-hydroxymethyl-2,2,9-trimethyl-4-(phenethylamino)-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol from an acetate ester solvent, an aliphatic hydrocarbon solvent, a nitrile solvent, an aromatic hydrocarbon solvent, a ketone solvent or an ether solvent, and crystal forms obtained according to the methods. | 03-08-2012 |
20120220773 | PYRIDINE CLASSICAL CANNABINOID COMPOUNDS AND RELATED METHODS OF USE - Disclosed are compounds of the formula I: | 08-30-2012 |
20130060037 | MATERIALS WITH AZA-DIBENZOTHIOPHENE OR AZA-DIBENZOFURAN CORE FOR PHOLED - A new class of compounds containing aza-dibenzothiophene or aza-dibenzofuran are provided. The compounds may be used in organic light emitting devices giving improved stability, improved efficiency, long lifetime and low operational voltage. In particular, the compounds may be used as the host material of an emissive layer having a host and an emissive dopant, or as a material in an enhancement layer. | 03-07-2013 |
20140094609 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR - The present invention is directed to an improved process for the preparation of Compounds of Formula (I), which are useful in the treatment of HIV infection. In particular, the present invention is directed to an improved process for the preparation of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid, which is useful in the treatment of HIV infection. | 04-03-2014 |
20140094610 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR - The present invention is directed to an improved process for the preparation of Compounds of Formula (I) or salts thereof which are useful in the treatment of HIV infection. In particular, the present invention is directed to an improved process for the preparation of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid or salt thereof which is useful in the treatment of HIV infection. | 04-03-2014 |
20160168161 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | 06-16-2016 |
546090000 | Plural ring oxygens in the tricyclo ring system | 10 |
20080227982 | SOLVENT FREE AMORPHOUS RAPAMYCIN - An improved process for coating implantable medical devices utilizes a number of techniques for improving the stability of therapeutic agents contained within the coating. The stability of the therapeutic agents may be improved by creating substantially solvent-free, amorphous forms of the therapeutic agents. | 09-18-2008 |
20090012298 | Process for the Preparation of Rapamycin Derivatives - Processes for the production of a 32-deoxorapamycin from a 32-iodo- or 32-hydroxyrapamycin, wherein the hydroxy group is substituted by the residue of an arylthionocarbonate or an arylthiocarbamate, in the presence of tris(trimethylsilyl)-silan and α,α′-azo-isobutyronitril in organic solvent; and 32-deoxorapamycin in the form of a crystalline solvate. | 01-08-2009 |
20090275754 | Narcotine Purification Process - A process for purifying Narcotine to remove color and impurities to form Noscapine. The process includes forming an aqueous isopropanol solution with the Narcotine product wherein the isopropanol concentration of the solution is about 20% to about 70% by volume; and adjusting the pH of the solution with a strong base to a pH of about 10 to about 14, wherein impurities are removed from the Narcotine product. | 11-05-2009 |
20100184985 | PROCESS FOR THE PRODUCTION OF MACROLIDES USING A NOVEL STRAIN, STREPTOMYCES SP. BICC 7522 - The present invention discloses a new strain of | 07-22-2010 |
20100249415 | Process for preparation of temsirolimus - The present invention provides two synthetic routes for the preparation of Temsirolimus (compound 1b and analog of Temsirolimus 1a). The first route includes the synthesis of CCI-779 by directly reacting rapamycin (4b) or Prolyl-rapamycin (4a) with substituent-2,2-bis(methoxy) propionic acid anhydride(11) in the presence of an organic base, followed by deprotection to give CCI-779 or Proline CCI-779. The second route includes a process involving a reaction of rapamycin-OH-31-sily ether (4d) or Prolyl-rapamycin-OH-31-sily ether (4c) with substituent-2,2-bis(methoxy) propionic acid anhydride(11) in the presence of an organic base and followed by subsequent hydrolysis step to obtain the desired CCI-779 or Proline CCI-779. | 09-30-2010 |
20130296572 | METHOD FOR PREPARING TEMSIROLIMUS - A method for preparing temsirolimus, the method including: using a substituted aromatic aldehyde to protect 2,2-dimethylol propionic acid to produce intermediate II; carrying out reaction between the intermediate II and 2,4,6-trichlorobenzoyl chloride; carrying out condensation reaction between a resulting product and rapamycin to produce intermediate III; and finally using sulfuric acid to remove a protecting group from the intermediate III to yield temsirolimus. | 11-07-2013 |
20140249312 | [1,3]DIOXOLO[4,5-G]QUINOLINE-6(5H)THIONE AND [1,3]DIOXOLO[4,5-G][1,2,4]TRIAZOLO[1,5-A]QUINOLINE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER - The present invention relates generally to [1,3]dioxolo[4,5-g]quinoline-6(5H)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives and/or compositions for use in inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcionoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types. | 09-04-2014 |
20150133666 | TRITOQUALINE FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS - The present invention relates to the use of a histamine H4 agonist molecule, the enantiomers of the (AMINO-7 TRIETHOXY-4,5,6 OXO-1 DIHYDRO-1,3 ISOBENZOFURANNYL-3)-1METHOXY-8 METHYL-2 METHYLENEDIOXY-6,7 TETRAHYDRO-,2,3,4 ISOQUINOLINE or tritoqualine for the treatment of respiratory impairment caused by cystic fibrosis and the reduction and prevention of bronchial superinfections. | 05-14-2015 |
20150148538 | USE OF AN H4 AGONIST MOLECULE TO TREAT ACUTE LEUKEMIA - The present invention relates to the use of new chemical substances, the levogyre and dextrogyre enantiomers of (AMINO-7 TRIETHOXY-4,5,6 OXO-1 DIHYDRO-1,3 ISOBENZOFURANNYL-3)-1 METHOXY-8 METHYL-2METHYLENEDIOXY-6,7 TETRAHYDRO-,2,3,4 ISOQUINOLEINE or tritoqualine, to treat acute myeloid or lymphoid leukemia, with the exception of type B leukemia. | 05-28-2015 |
20150148539 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof - The present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial. | 05-28-2015 |
546091000 | Tropane and oxirane in the tricyclo ring system | 5 |
20100063289 | METHOD FOR PRODUCING AMMONIUM HEXAFLUOROPHOSPHATES - The invention relates to a method for producing ammonium hexafluorophosphates of general formula (1) wherein R | 03-11-2010 |
20100197922 | AZABICYCLOALKANE COMPOUNDS - This invention provides compounds of formula I: | 08-05-2010 |
20120046467 | QUATERNARY AMMONIUM SALT COMPOUNDS | 02-23-2012 |
20130165656 | CONTINUOUS PROCESS FOR THE ALKYLATION OF CYCLIC TERTIARY AMINES - A continuous process for the alkylation of tertiary amines and, in particular, to a continuous process for the quaternization of cyclic tertiary amines useful for the preparation of cyclic quaternary ammonium salts with high purity is described. | 06-27-2013 |
20140171645 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE - The present invention provides electrophilic alkylating reagents of formula II, wherein is an aryl group, R | 06-19-2014 |
546092000 | Plural chalcogens bonded directly to ring carbons of the tricyclo ring system | 3 |
20090312554 | Novel Process for the Preparation of Hexacyclic Compounds - This invention relates to novel processes for the preparation of compounds of the formula [1], | 12-17-2009 |
20130225823 | PROCESSES FOR PREPARATION OF EVEROLIMUS AND INTERMEDIATES THEREOF - The present disclosure discloses processes of Everolimus and intermediates: reacting Sirolimus (Rapamycin) under solvent free conditions with appropriate side chain implying portion wise additions, one pot conversion, and resin mediated synthesis. | 08-29-2013 |
20150376199 | A METHOD FOR PREPARING (+)-TRICYCLIC HYDROXYL LACTONE - The invention belongs to the technical field of organic chemistry, in particular being a method for preparing (+)-tricyclic hydroxyl lactone. The preparation of the (+)-tricyclic hydroxyl lactone compound in the prior art has lengthy steps, low stereoselectivity and high costs. The (+)-tricyclic hydroxyl lactone of the invention is obtained by an asymmetric oxidation reaction of prochiral tricyclic lactones in an organic solvent with an optically active Davis oxidant in the presence of an organic base. The method of the invention uses easily available raw materials, has low costs, good selectivity, and is suitable for large-scale preparation. | 12-31-2015 |